Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (May 2025)
28 slides from Adalta's investor presentation, May 7, 2025
Slide 1: Commercialising Cellular Immunotherapies East to West
For personal use only COMMERCIALISING CELLULAR IMMUNOTHERAPIES “EAST TO WEST” ADALTA LIMITED (ASX:1AD) | INVESTOR PRESENTATION | MAY 2025 AdAlta Limited (ASX:1AD) | Investor Presentation | May 2025 | 1
Slide 2: Important Notice & Disclaimer
IMPORTANT NOTICE & DISCLAIMER Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. For personal use only This presentation is
Slide 3: AdAlta: Next Generation Cell & Protein Therapeutics
ADALTA: NEXT GENERATION CELL & PROTEIN THERAPEUTICS “East to West” cellular immunotherapy strategy In-license next generation clinical stage assets from Asia, establish For personal use only Western manufacturing and generate clinical data for on-licensing Leverages our unique skills, regional ecosy
Slide 4: AdAlta's Renounceable Rights Offer
ADALTA’S RENOUNCEABLE RIGHTS OFFER INDICATIVE TIMETABLE DATE Renounceable offer of two (2) New Shares for every three (3) Shares held by Lodge transaction specific prospectus with ASIC and give to ASX Monday 5 May 2025 Eligible Shareholders at the Record Date Lodge appendix 3B applying for quotation
Slide 5: East to West Strategy Central to AdAlta's Growth
For personal use only “EAST TO WEST” STRATEGY CENTRAL TO ADALTA’S GROWTH AdAlta Limited (ASX:1AD) | Investor Presentation | May 2025 | 55
Slide 6: East to West Strategy Overview
“EAST TO WEST” STRATEGY OVERVIEW Substantial value inflection potential by bringing “Eastern” cellular For personal use only immunotherapy innovations to “Western” regulated markets AdAlta has clear aspirational growth targets for its Combining Asia's innovative T cell therapies for solid cancers an
Slide 7: Rationale for Our Strategy
RATIONALE FOR OUR STRATEGY Market Opportunity Competitive Advantage First Assets For personal use only Cancers that are solid • Networks: Asia's rich innovation, Initial three assets under term sheet from tumours and remain Australia's clinical and manufacturing pipeline of 10 high-potential therapi
Slide 8: Becoming a Valuation Multiplier for Asian Partners
BECOMING A VALUATION MULTIPLIER FOR ASIAN PARTNERS For personal use only 3 In-license market leading 3 assets from Asia (“East”): 1 Low acquisition cost. By financing to next inflection On-licensing: point AdAlta acquires a Establish global share of the asset at exit manufacturing network and on-lic
Slide 9: Value at Exit: Phase I CAR-T Licensing Transactions
VALUE AT EXIT: PHASE I CAR-T LICENSING TRANSACTIONS Total Upfront Date Drug(s) Licensor Licensee Deal stage Lead indications value (US$m) (US$m) For personal use only MAGE-A4 targeting TCR T Phase 2 May-24 Head & neck cancer 665 85 cell therapy (ongoing; global) DLL3 targeting autologous Phase 1 Nov
Slide 10: Progress and Potential
PROGRESS AND POTENTIAL Asset acquisition stream Australian clinical • Technical and on-site diligence essentially complete trial data facilitates • Minor adjustments to timelines, sequencing and financial We are here pivotal studies, For personal use only milestones being finalized – on track for fi
Slide 11: Three Assets Under Exclusive Due Diligence
THREE ASSETS UNDER EXCLUSIVE DUE DILIGENCE Armored-CAR-T term sheet #1 CAR-T term sheet #2 CAR-T term sheet #3 Lung, mesothelioma, ovarian, cervical, Epithelial solid cancers incl. colorectal, Gastric, gynaecological and other Field For personal use only pancreatic, colorectal lung and gastric epith
Slide 12: 1. First in Class Armoured CAR-T
1. FIRST IN CLASS ARMOURED CAR-T Target market Advanced, solid cancer patient: • Mesothelioma, lung cancer plus ovarian, cervical, pancreatic, colorectal sustained response to armored-CAR-T For personal use only • More than 1.5 million relapsed, refractory or metastatic patients requiring second-lin
Slide 13: 2. First in Class CAR-T
2. FIRST IN CLASS CAR-T Target market • Colorectal cancer and a wide range of epithelial solid cancers including gastric and lung Complete resolution of For personal use only • More than 1.5 million relapsed or refractory patients worldwide each year malignant ascites in Stage IV GI cancer patient •
Slide 14: 3. First in Class CAR-T
3. FIRST IN CLASS CAR-T Target market • Gastric cancer and other epithelial cancers including gynaecological cancers Comparative efficacy versus For personal use only • More than 1.5 million relapsed or refractory patients worldwide each year standard of care • 150,000 advanced gastric cancer patien
Slide 15: AD-214: A New Approach to Fibrosis
For personal use only AD-214: A NEW APPROACH TO FIBROSIS AVAILABLE FOR PARTNERING AdAlta Limited (ASX:1AD) | Investor Presentation | May 2025 | 15 15
Slide 16: Monetising Fibrosis Disease Drug Candidate AD-214
MONETISING FIBROSIS DISEASE DRUG CANDIDATE AD-214 Investment to date has built strong value proposition Key Priority: Seek out-licensing or third-party investment to For personal use only unlock next level of value First in class molecule targeting established mode ✓ Competitively positioned as only
Slide 17: Underserved and Large Fibrotic Disease Market
UNDERSERVED AND LARGE FIBROTIC DISEASE MARKET IPF market is underserved today Many other fibrosis market opportunities2 For personal use only • Poor efficacy: Existing therapies slow but do not halt progression and do not significantly extend life expectancy • Side effects: Their side effects result
Slide 18: Pharma Companies Value IPF/Fibrosis Assets
PHARMA COMPANIES VALUE IPF/FIBROSIS ASSETS Upfront payment to Contingent Clinical Phase at Date Licensor/target Licensee/acquirer Transaction licensor milestones transaction For personal use only Aug-22 License US$100m US$600m 2 complete Apr-20 Acquisition US$45m Not disclosed 2a complete Nov-19 Acq
Slide 19: WD-34 i-body: A Potential Breakthrough in Malaria
For personal use only WD-34 I-BODY: A POTENTIAL BREAKTHROUGH IN MALARIA AVAILABLE FOR PARTNERING AdAlta Limited (ASX:1AD) | Investor Presentation | May 2025 | 19 19
Slide 20: World First Pan-Species High Potency Anti-Malarial
WORLD FIRST PAN-SPECIES HIGH POTENCY ANTI-MALARIAL WD-34 i-body has potential to transform malaria treatment Strategy: seeking non-dilutive and commercial For personal use only ✓ 247 million cases, 619,000 deaths in 20211 partners to advance outside AdAlta Malaria remains a ✓ Re-emerging in US and E
Slide 21: Corporate Information
For personal use only CORPORATE INFORMATION AdAlta Limited (ASX:1AD) | Investor Presentation | May 2025 | 21 21
Slide 22: Corporate Snapshot
CORPORATE SNAPSHOT AdAlta Limited For personal use only Code ASX:1AD Specialist in next-generation cell and protein therapeutics for fatal diseases Market Capitalisation $4.0m Enterprise Value $3.2m First three term sheets signed of "East-to- Cash (31 March 2025) $0.8m West" cell therapy strategy, w
Slide 23: Experienced Team with Global Reach
EXPERIENCED TEAM WITH GLOBAL REACH Board Executive “East-to-West” Strategy AD-214: Fibrosis For personal use only Paul MacLeman, DVM Angus Tester, PhD Kevin Lynch TBA - engaged Chair Senior Manager, Consultant CMO Consultant CMO Projects and Programs Tim Oldham, PhD Prof Andrew Wilks Joseph Tyler CE
Slide 24: Transaction-Based Growth Strategy is Being Delivered
TRANSACTION-BASED GROWTH STRATEGY IS BEING DELIVERED For personal use only “East to West” cellular The first three assets under Experienced team and accessible immunotherapy growth strategy exclusive due diligence for the “East global network ready to execute a leveraging regional and business to We
Slide 25: For More Information Please Contact
For personal use only FOR MORE INFORMATION PLEASE CONTACT: TIM OLDHAM CEO & MANAGING DIRECTOR +61 403 446 665 [email protected] [email protected] WWW.ADALTA.COM.AU AdAlta Limited (ASX:1AD) | Investor Presentation | May 2025 | 25
Slide 26: The Market Opportunity
THE MARKET OPPORTUNITY T cell solid cancer therapy: the next frontier for cellular immunotherapy For personal use only In 2024, FDA approved two What is T-cell therapy? 6 FDA-approved CAR-T T cell therapies for solid therapies since 2017 cancer (melanoma, Involves re-engineering and transformed bloo
Slide 27: Accessing Quality Assets from Asia
ACCESSING QUALITY ASSETS FROM ASIA Quality Asia cellular Flow of innovation from Asia to the West is hampered by: lack of capital in Asia, lack of Western immunotherapy pipeline, experience and networks, opportunity cost for large biopharma to conduct due diligence, difficulty For personal use only
Slide 28: Leveraging AdAlta's Competitive Advantages
LEVERAGING ADALTA’S COMPETITIVE ADVANTAGES Strategic asset sourcing discipline Capital-light and risk managed For personal use only • T cell therapies for solid cancers • AdAlta managed; JV/asset financed • Differentiated, multi-functional • Defined investment in clinically product design derisked a